Raras
Buscar doenças, sintomas, genes...
Meningioma familiar múltiplo
ORPHA:263662CID-10 · D32.9CID-11 · 2A01.00DOENÇA RARA

Meningioma múltiplo familiar é um tumor benigno raro do sistema nervoso central, que se caracteriza pelo surgimento de múltiplos meningiomas ou, raramente, de um único, em dois ou mais parentes de sangue, sem outros sinais aparentes de síndromes. Dependendo da localização, da velocidade de crescimento e do tamanho dos tumores, os pacientes podem apresentar um comprometimento neurológico sutil, que piora gradualmente, ou um comprometimento súbito e grave, ou podem ser completamente assintomáticos.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Meningioma múltiplo familiar é um tumor benigno raro do sistema nervoso central, que se caracteriza pelo surgimento de múltiplos meningiomas ou, raramente, de um único, em dois ou mais parentes de sangue, sem outros sinais aparentes de síndromes. Dependendo da localização, da velocidade de crescimento e do tamanho dos tumores, os pacientes podem apresentar um comprometimento neurológico sutil, que piora gradualmente, ou um comprometimento súbito e grave, ou podem ser completamente assintomáticos.

Publicações científicas
563 artigos
Último publicado: 2025

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: D32.9
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico563PubMed
Últimos 10 anos200publicações
Pico202341 papers
Linha do tempo
2026Hoje · 2026📈 2023Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

5 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant.

MN1Transcriptional activator MN1Candidate gene tested inAltamente restrito
FUNÇÃO

Transcriptional activator which specifically regulates expression of TBX22 in the posterior region of the developing palate. Required during later stages of palate development for growth and medial fusion of the palatal shelves. Promotes maturation and normal function of calvarial osteoblasts, including expression of the osteoclastogenic cytokine TNFSF11/RANKL. Necessary for normal development of the membranous bones of the skull (By similarity). May play a role in tumor suppression (Probable)

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

CEBALID syndrome

An autosomal dominant developmental disorder characterized by global developmental delay, intellectual disability with severe expressive language delay, craniofacial dysmorphism, and structural brain abnormalities. Most patients have an atypical form of rhombencephalosynapsis, a distinctive brain malformation characterized by partial or complete loss of the cerebellar vermis with fusion of the cerebellar hemispheres. Other frequent features include perisylvian polymicrogyria, abnormal posterior clinoid processes, cerebellar hypoplasia or dysplasia, and persistent trigeminal artery.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
46.4 TPM
Músculo esquelético
35.8 TPM
Aorta
35.1 TPM
Artéria coronária
27.7 TPM
Esôfago - Junção
22.0 TPM
INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (3)
familial meningiomaCEBALID syndromefamilial multiple meningioma
HGNC:7180UniProt:Q10571
SMARCE1SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1Disease-causing germline mutation(s) (loss of function) inAltamente restrito
FUNÇÃO

Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). Durin

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (8)
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not knownRMTs methylate histone argininesFormation of neuronal progenitor and neuronal BAF (npBAF and nBAF)Formation of the embryonic stem cell BAF (esBAF) complexFormation of the polybromo-BAF (pBAF) complex
MECANISMO DE DOENÇA

Meningioma

A common neoplasm of the central nervous system derived from arachnoidal cells. The majority of meningiomas are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Most cases are sporadic. Familial occurrence of meningioma is rare.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
58.4 TPM
Cervix Endocervix
51.0 TPM
Fibroblastos
47.8 TPM
Artéria tibial
45.6 TPM
Cervix Ectocervix
45.5 TPM
OUTRAS DOENÇAS (5)
Coffin-Siris syndrome 5familial multiple meningiomameningiomaCoffin-Siris syndrome
HGNC:11109UniProt:Q969G3
SUFUSuppressor of fused homologMajor susceptibility factor inAltamente restrito
FUNÇÃO

Negative regulator in the hedgehog/smoothened signaling pathway (PubMed:10559945, PubMed:10564661, PubMed:10806483, PubMed:12068298, PubMed:12975309, PubMed:15367681, PubMed:22365972, PubMed:24217340, PubMed:24311597, PubMed:27234298, PubMed:28965847). Down-regulates GLI1-mediated transactivation of target genes (PubMed:15367681, PubMed:24217340, PubMed:24311597). Down-regulates GLI2-mediated transactivation of target genes (PubMed:24217340, PubMed:24311597). Part of a corepressor complex that a

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (4)
GLI3 is processed to GLI3R by the proteasomeHedgehog 'off' stateDegradation of GLI1 by the proteasomeDegradation of GLI2 by the proteasome
MECANISMO DE DOENÇA

Medulloblastoma

Malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children.

EXPRESSÃO TECIDUAL(Ubíquo)
Skin Sun Exposed Lower leg
19.1 TPM
Testículo
17.1 TPM
Skin Not Sun Exposed Suprapubic
16.1 TPM
Nervo tibial
15.3 TPM
Útero
14.5 TPM
OUTRAS DOENÇAS (11)
Joubert syndrome 32basal cell nevus syndrome 2familial multiple meningiomamedulloblastoma with extensive nodularity
HGNC:16466UniProt:Q9UMX1
SMARCB1SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Core component of the BAF (hSWI/SNF) complex. This ATP-dependent chromatin-remodeling complex plays important roles in cell proliferation and differentiation, in cellular antiviral activities and inhibition of tumor formation. The BAF complex is able to create a stable, altered form of chromatin that constrains fewer negative supercoils than normal. This change in supercoiling would be due to the conversion of up to one-half of the nucleosomes on polynucleosomal arrays into asymmetric structures

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (8)
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not knownRMTs methylate histone argininesFormation of neuronal progenitor and neuronal BAF (npBAF and nBAF)Formation of the embryonic stem cell BAF (esBAF) complexFormation of the polybromo-BAF (pBAF) complex
MECANISMO DE DOENÇA

Rhabdoid tumor predisposition syndrome 1

A familial cancer syndrome predisposing to renal or extrarenal malignant rhabdoid tumors and to a variety of tumors of the central nervous system, including choroid plexus carcinoma, medulloblastoma, and central primitive neuroectodermal tumors. Rhabdoid tumors are the most aggressive and lethal malignancies occurring in early childhood.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
136.4 TPM
Testículo
110.5 TPM
Cérebro - Hemisfério cerebelar
98.7 TPM
Cerebelo
93.5 TPM
Ovário
93.2 TPM
OUTRAS DOENÇAS (9)
rhabdoid tumor predisposition syndrome 1intellectual disability, autosomal dominant 15familial multiple meningiomaschwannomatosis
HGNC:11103UniProt:Q12824
PDGFBPlatelet-derived growth factor subunit BCandidate gene tested inAltamente restrito
FUNÇÃO

Growth factor that plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis. Potent mitogen for cells of mesenchymal origin (PubMed:26599395). Required for normal proliferation and recruitment of pericytes and vascular smooth muscle cells in the central nervous system, skin, lung, heart and placenta. Required for normal blood vessel development, and for normal development of kidney glomeruli. Plays an important role in wound

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (8)
PI5P, PP2A and IER3 Regulate PI3K/AKT SignalingPIP3 activates AKT signalingConstitutive Signaling by Aberrant PI3K in CancerDownstream signal transductionRAF/MAP kinase cascade
MECANISMO DE DOENÇA

Basal ganglia calcification, idiopathic, 5

A form of basal ganglia calcification, an autosomal dominant condition characterized by symmetric calcification in the basal ganglia and other brain regions. Affected individuals can either be asymptomatic or show a wide spectrum of neuropsychiatric symptoms, including parkinsonism, dystonia, tremor, ataxia, dementia, psychosis, seizures, and chronic headache. Serum levels of calcium, phosphate, alkaline phosphatase and parathyroid hormone are normal. The neuropathological hallmark of the disease is vascular and pericapillary calcification, mainly of calcium phosphate, in the affected brain areas.

EXPRESSÃO TECIDUAL(Ubíquo)
Tecido adiposo
49.1 TPM
Pulmão
45.8 TPM
Adipose Visceral Omentum
43.1 TPM
Mama
34.1 TPM
Tireoide
30.5 TPM
OUTRAS DOENÇAS (6)
familial meningiomabasal ganglia calcification, idiopathic, 5familial multiple meningiomameningioma
HGNC:8800UniProt:P01127

Variantes genéticas (ClinVar)

1,738 variantes patogênicas registradas no ClinVar.

🧬 PDGFB: NM_002608.4(PDGFB):c.251-1G>T ()
🧬 PDGFB: NM_002608.4(PDGFB):c.107_110del (p.His36fs) ()
🧬 PDGFB: NM_002608.4(PDGFB):c.63+1G>A ()
🧬 PDGFB: NM_002608.4(PDGFB):c.33_34del (p.Cys12fs) ()
🧬 PDGFB: NM_002608.4(PDGFB):c.584dup (p.Ser196fs) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 1 variantes classificadas pelo ClinVar.

1
Patogênica (100.0%)
VARIANTES MAIS SIGNIFICATIVAS
LOC130067016: NM_006767.4(LZTR1):c.102C>A (p.Cys34Ter) [Likely pathogenic]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Meningioma familiar múltiplo

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

STING activation induces cytotoxic and immune responses in meningiomas via inflammatory cell death pathways.

Nature communications2026 Feb 12

Meningiomas are common tumors of the central nervous system that are typically treated with surgery or radiation, but lack established systemic therapies. Activation of the stimulator of interferon genes pathway with an agonist such as 8803 can trigger anti-tumor immune responses. Using integrated molecular approaches, here we show that this pathway is targetable in both neoplastic and immune populations within the meningioma microenvironment. Meningioma tumor cells exhibit promoter hypomethylation and increased chromatin accessibility of the STING genomic locus, associated with robust expression of this gene. Treatment of diverse patient meningiomas ex vivo with 8803 induces direct tumor cytotoxicity through inflammatory cell death pathways, including induction of gasdermin D membrane pore formation. Release of necrotic tumor debris triggered by 8803 activates macrophages and upregulates matrix metalloproteinase production, facilitating degradation of extra-cellular collagen. Injection of preclinical meningiomas with 8803 induces survival benefits, including in an immunocompetent orthotopic setting, through remodeling of the tumor microenvironment, immune infiltration, and downregulation of tumor-mediated immune suppression, thereby nominating 8803 for treatment consideration in meningiomas.

#2

Association Between miRNAs and the Diagnosis, Prognosis, and Recurrence of Patients with Meningioma: A Systematic Review.

Cellular and molecular neurobiology2026 Feb 07

To evaluate the diagnostic, prognostic, and recurrence-related roles of microRNAs (miRNAs) in meningioma based on expression profiles across different biological samples. This systematic review was conducted in accordance with Cochrane Collaboration and PRISMA guidelines. A search was performed in PubMed, Scopus, Web of Science, and Google Scholar without language restrictions. Cohort and case–control studies assessing miRNA expression in tumor tissue, serum, or cerebrospinal fluid from patients with histologically confirmed meningioma were included. Risk of bias was evaluated using the Newcastle–Ottawa Scale. Bioinformatic pathway enrichment analyses were conducted for recurrently miRNAs. Twenty-three studies involving 1615 participants were included, of whom 1461 had meningiomas (WHO grades 1–3). Overall, 153 miRNAs were evaluated, including 90 upregulated, 45 downregulated, and 18 without significant differential expression. miR-21, miR-34a, and members of the miR-181 family were consistently associated with tumor grade and progression. Tumor recurrence was most frequently linked to miR-224-5p, miR-331-5p, miR-29c-3p, and miR-219-5p. Circulating miRNAs, particularly miR-497 and miR-219, demonstrated diagnostic potential in serum and cerebrospinal fluid. Pathway analyses highlighted enrichment in metabolic and signaling pathways, including sphingolipid, sulfur, and fatty acid metabolism. This review identifies miR-21, miR-224-5p, miR-331-5p, miR-29c-3p, and circulating miR-497 and miR-219 as the most promising miRNA biomarkers for meningioma diagnosis, grading, and recurrence monitoring. Despite methodological heterogeneity, the consistency of these findings across independent studies supports their translational potential. Nonetheless, large, standardized studies with independent validation cohorts are required prior to clinical implementation. The online version contains supplementary material available at 10.1007/s10571-026-01665-2.

#3

KMT2C Loss Promotes NF2-Wildtype Meningioma Progression and Ferroptosis Sensitivity via Epigenetic Repression of Hippo Signaling.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)2026 Feb 05

High-grade meningiomas remain clinically challenging due to their aggressive behavior and limited therapeutic options. Although mutations and dysregulation of KMT2 family members have been implicated in various cancers, their functional significance in meningioma remains unclear. While NF2 alterations are the most common drivers of meningioma pathogenesis, the mechanisms regulating NF2 transcription in NF2-intact tumors are poorly understood. Here, we demonstrate that KMT2C expression is markedly reduced in high-grade meningiomas and that loss of KMT2C promotes proliferation and invasion in NF2-wild-type meningioma cells. Mechanistically, KMT2C deficiency suppresses NF2 transcription and inactivates Hippo signaling, leading to enhanced oncogenic activity and increased sensitivity to ferroptosis. Loss of KMT2C impairs the acetyltransferase activity of CBP/EP300, resulting in a global reduction of H3K27ac and transcriptional silencing of NF2. Pharmacological restoration of histone acetylation with the HDAC inhibitor Trichostatin A (TSA) effectively suppressed tumor growth. Collectively, our findings identify KMT2C as a key epigenetic regulator linking promoter histone acetylation, NF2-Hippo pathway activity, and ferroptosis susceptibility. These results provide mechanistic insights into high-grade meningioma progression and highlight ferroptosis induction and epigenetic modulation as promising therapeutic strategies for NF2-wild-type, KMT2C-deficient meningiomas.

#4

Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis.

Annals of internal medicine2026 Feb

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used for type 2 diabetes mellitus (T2DM) and overweight or obesity, but their association with cancer is unclear. To investigate the risk for obesity-related cancer associated with GLP-1RAs. PubMed, Embase, Web of Science, Scopus, and the Cochrane Central Register of Controlled Trials from inception to August 2025. Randomized placebo-controlled trials reporting any of the following cancer outcomes: thyroid, pancreatic, colorectal, gastric, esophageal, liver, gallbladder, breast, ovarian, endometrial, or kidney cancer; multiple myeloma; or meningioma. Risk of bias was evaluated using the Cochrane Risk of Bias 2 tool, and certainty of evidence was assessed using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Odds ratios (ORs) were pooled using random-effects meta-analysis. The review included 48 trials involving 94 245 participants. GLP-1RAs probably have little or no effect on risk for thyroid cancer (OR, 1.37 [95% CI, 0.82 to 2.31]; 1 fewer to 9 more cases per 10 000 patients treated), pancreatic cancer (OR, 0.84 [CI, 0.53 to 1.35]; 9 fewer to 6 more per 10 000), breast cancer (OR, 0.95 [CI, 0.60 to 1.49]; 10 fewer to 12 more per 10 000), or kidney cancer (OR, 1.12 [CI, 0.78 to 1.60]; 5 fewer to 13 more per 10 000) (moderate certainty). GLP-1RAs may have little or no effect on colorectal, esophageal, liver, gallbladder, ovarian, or endometrial cancer; multiple myeloma; or meningioma (low certainty). The effect on gastric cancer is very uncertain. Results were consistent in sensitivity analyses of trials with low risk of bias and studies of semaglutide or tirzepatide and across subgroups stratified by follow-up duration, population, GLP-1RA class, weight loss profile, dose, and duration of action. The included trials were not designed to evaluate cancer outcomes and had short follow-up. GLP-1RAs may have little or no effect on risk for obesity-related cancers. Longer-term studies are needed to clarify potential risks or benefits. None. (PROSPERO: CRD42024608365). LZTR1- and SMARCB1-related schwannomatosis are characterized by a predisposition to develop multiple non-intradermal schwannomas. Individuals most commonly present between the second and fourth decade of life. The most common presenting feature is localized or diffuse pain or asymptomatic mass. Schwannomas most often affect peripheral nerves and spinal nerves. Meningiomas have only been reported in individuals with SMARCB1-related schwannomatosis. Malignancy remains a risk especially in individuals with SMARCB1-related schwannomatosis. The diagnosis of LZTR1- or SMARCB1-related schwannomatosis is established in a proband with characteristic clinical findings and a heterozygous germline pathogenic variant in LZTR1 or SMARCB1 identified by molecular genetic testing. Treatment of manifestations: Comprehensive, multimodal approach to pain management, guided by a pain management specialist or neurologist; referral to mental health professionals as needed for anxiety and/or depression; surgery for schwannomas associated with uncontrolled localized pain or a neurologic deficit; meningioma treatment as for sporadic meningioma. Surveillance: Annual neurologic examination and pain assessment; brain and spine MRI or whole-body MRI every two to three years beginning at age 12 years, with fine cuts through internal auditory canal in those w/LZTR1-related schwannomatosis; assessment for anxiety and depression annually or as needed. Agents/circumstances to avoid: Radiation can increase the risk for malignant transformation and should be avoided when possible. Evaluation of relatives at risk: It is appropriate to evaluate apparently asymptomatic older and younger at-risk relatives of an affected individual in order to identify as early as possible those who would benefit from surveillance and clinical management. LZTR1- and SMARCB1-related schwannomatosis are inherited in an autosomal dominant manner with reduced penetrance. Fewer than 20% of individuals diagnosed with LZTR1- or SMARCB1-related schwannomatosis have an affected parent. In families in which the proband represents a simplex case, the proportion of probands with a de novo pathogenic variant is approximately 30% for LZTR1-related schwannomatosis and 10% for SMARCB1-related schwannomatosis. Each child of an individual with LZTR1- or SMARCB1-related schwannomatosis has up to a 50% chance of inheriting a pathogenic variant. Once a germline LZTR1 or SMARCB1 pathogenic variant has been identified in an affected family member, predictive testing for at-risk asymptomatic family members and prenatal and preimplantation genetic testing are possible.

#5

French translation and preliminary psychometric evaluation of the Meningioma Quality of Life questionnaire (MQOL-FR).

Neuro-Chirurgie2026 Mar 20

Disease-specific instruments to assess quality of life in meningioma patients are scarce, and no validated French meningioma-specific questionnaire is available. We translated the Meningioma Quality of Life questionnaire (MQOL) into French (MQOL-FR) and performed a preliminary psychometric evaluation focused on the total score. In this prospective study of adults with meningioma, MQOL was translated using the EORTC forward-backward procedure with expert-panel reconciliation. Patients completed MQOL-FR, Karnofsky Performance Status (KPS), Functional Assessment of Cancer Therapy-Brain (FACT-Br), and EQ-5D. Internal consistency (Cronbach's alpha), test-retest reliability (intraclass correlation coefficient (ICC), and convergent validity (Pearson correlations) were assessed using available complete data for each score. Of 56 invited patients, 37 completed at least part of MQOL-FR. Across subscales, 32-36 patients contributed to internal consistency analyses, and 26 provided complete data for the MQOL total score (all scorable items completed; item 69 "non applicable/non-scored"). Cronbach's alpha for the total score was 0.88 (95%CI 0.75-0.95). Several subscales (symptoms, emotional, anxiety, functional well-being) showed acceptable reliability, whereas others (vitality, family, social, physical) were less robust. Thirteen patients completed the questionnaire twice; nine had complete paired total-score data. Test-retest reliability for the total score was excellent (ICC 0.93, 95%CI 0.71-0.98). Measurement error indices were SEM 3.8 points and MDC95 10.6 points (0-100 scale). The MQOL total score correlated strongly with the FACT-Br total score (r = 0.84). MQOL-FR showed good internal consistency and excellent test-retest reliability for the total score, with encouraging convergent validity in this cohort. Subscale-level findings should be considered exploratory. Larger multicenter studies are needed to refine subscale performance, evaluate responsiveness to clinical change, and support broader validation in more representative samples.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC1 artigos no totalmostrando 197

2026

French translation and preliminary psychometric evaluation of the Meningioma Quality of Life questionnaire (MQOL-FR).

Neuro-Chirurgie
2026

Brain tumor classification using optimized ResNet50 with dynamic precision optimization for enhanced speed and diagnostic accuracy.

Scientific reports
2026

STING activation induces cytotoxic and immune responses in meningiomas via inflammatory cell death pathways.

Nature communications
2026

High frequency and unique subtypes of meningioma in patients with BAP1 tumor predisposition syndrome.

Journal of neuro-oncology
2026

Association Between miRNAs and the Diagnosis, Prognosis, and Recurrence of Patients with Meningioma: A Systematic Review.

Cellular and molecular neurobiology
2026

KMT2C Loss Promotes NF2-Wildtype Meningioma Progression and Ferroptosis Sensitivity via Epigenetic Repression of Hippo Signaling.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2026

Intracranial mesenchymal tumor, FET::CREB fusion-positive: an integrative analysis of 81 cases.

Neuro-oncology
2026

Quality of life in Slovenian patients with skull base tumours: cross-cultural adaptation and validation of a Slovenian skull base inventory.

Radiology and oncology
2026

Functional connectivity in electroencephalography of brain tumor patients in status epilepticus: a retrospective evaluation of prognostic value.

Quantitative imaging in medicine and surgery
2025

Identification of BAP1 Germline Mutation in a Pediatric Patient With Skull Base Meningioma.

Journal of child neurology
2025

Recognition of an Intracranial Meningioma in a Woman With Worsening Headache Presenting to a Chiropractor: A Case Report.

Cureus
2026

Combining Brigatinib with mTOR Inhibition to Effectively Treat NF2-SWN-Associated and Sporadic NF2-Deficient Meningiomas.

Cancer research communications
2025

Whorls in the Lung: A Case of Primary Pulmonary Meningioma.

Cureus
2025

TRAF7 in signaling and disease: emerging mechanisms and clinical implications.

Molecular medicine (Cambridge, Mass.)
2026

Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis.

Annals of internal medicine
2025

Histopathologic risk factors for progression of atypical meningioma: a retrospective cohort study evaluating the impact and clinical value of mitotic count and Ki-67.

Acta neurochirurgica
2026

Mounting evidence implicates medroxyprogesterone acetate in meningioma risk, but mechanisms require further investigation.

Neuro-oncology
2025

Patho-radiological concordance in brain tumors - A retrospective study.

Bioinformation
2025

Osteosclerosis and Meningioma: Implicating the Tumor Suppressor Gene AMER1/WTX.

Anticancer research
2025

Gut Microbiota Influences Meningioma Pathogenesis via Circulating Metabolites: A Two-Sample Mendelian Randomization Study.

Brain and behavior
2025

Chronological and Biological Age in Predicting Outcomes of Older Patients in Neurosurgery.

Neurologia medico-chirurgica
2025

Emerging targeted therapies in meningiomas.

Current opinion in neurology
2026

Incorporation of optical profilometry volume correction in quantitative elemental bioimaging workflows.

Talanta
2025

Adiposity distribution and risks of 12 obesity-related cancers: a Mendelian randomization analysis.

Journal of the National Cancer Institute
2025

Preoperative embolization improves local control and modulates gene expression in atypical WHO grade 2 meningioma.

Neuro-oncology
2025

The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis.

The Lancet. Oncology
2025

Brain tumors linked to Chernobyl radiation exposure: a case study and historical perspective. Illustrative cases.

Journal of neurosurgery. Case lessons
2025

[Dynamics of caudal cranial nerves' functions after resection of ventrolateral craniovertebral meningioma: clinical case and literature review].

Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko
2025

The concept, intention, and evaluation of the term treatment-refractory meningioma.

Journal of neuro-oncology
2025

Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells.

Neuro-oncology
2025

A large occipital meningioma with minimal symptoms in a 40-year old female: a rare case report from Syria.

Annals of medicine and surgery (2012)
2025

Two pediatric patients with secondary glioblastoma following radiotherapy for acute lymphoblastic leukemia: a case report.

World journal of surgical oncology
2025

Intracranial mesenchymal tumor with EWSR1-rearrangement (FET::CREB family): A case series with clinico-radiological and pathological correlation and review of literature.

Clinical neuropathology
2025

Postoperative radiotherapy in subtotally resected recurrent WHO grade 1 meningiomas with intermediate-/high-risk molecular profiles.

Neuro-oncology
2025

Incidental pediatric intraparenchymal meningioma: illustrative case.

Journal of neurosurgery. Case lessons
2025

Novel germline and somatic variants in familial and sporadic meningioma genes.

NPJ genomic medicine
2025

Society of Family Planning Clinical Recommendation: Contraceptive considerations for individuals with cancer and cancer survivors part 3 - Skin, blood, gastrointestinal, liver, lung, central nervous system, and other cancers: Joint with the Society of Gynecologic Oncology.

Contraception
2025

A Case Report Depicting a Rare Neurosurgical Disease: Aggressive Meningiomatosis.

Journal of clinical medicine
2025

Managing Hashimoto's Encephalopathy: A Case Report.

Cureus
2025

Supraorbital keyhole approach (SOKHA) versus endoscopic endonasal approach (EEA) for suprasellar meningioma (SSM) resection: systematic review and meta-analysis.

Annals of medicine and surgery (2012)
2025

Missense genetic variant in IQCA1 gene in patients with meningioma.

Acta neurologica Belgica
2025

Meningioma: Novel Diagnostic and Therapeutic Approaches.

Biomedicines
2025

A thematic analysis of shared decision-making in consultations with patients with a presumed brain tumor and neurosurgeons.

Neuro-oncology practice
2025

ARMC5 mutations in primary bilateral macronodular adrenal hyperplasia: a family case report.

BMC medical genomics
2025

Survival differences in malignant meningiomas: a latent class analysis using SEER data.

Discover oncology
2025

Anaplastic meningioma in a 6-year-old with somatic YAP1::MAML2 fusion and multiple endocrine neoplasia type 4 (MEN4) syndrome.

Cancer genetics
2025

Advancements in the research of the structure, function, and disease-related roles of ARMC5.

Frontiers of medicine
2025

NF2 loss-of-function and hypoxia drive radiation resistance in grade 2 meningiomas.

Journal of the National Cancer Institute
2025

Impact of 2021 World Health Organization Grading, Peritumoral Edema, and Radiotherapy on the Recurrence of a Grossly Resected Intracranial Meningiomas: A Ten-Year Follow-Up Study.

World journal of oncology
2025

Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design.

Neuro-oncology
2025

A Patient With Intracranial Multiple Meningiomas Combined With Neurofibromatosis type I.

The Journal of craniofacial surgery
2024

A novel mutation in SMARCB1 associated with adult Coffin-Siris syndrome and meningioma.

Acta biochimica et biophysica Sinica
2024

Novel therapies for pediatric low grade glioma.

Current opinion in neurology
2024

A rare association of pheochromocytoma, paraganglioma, and pituitary adenoma (3PA): A case report and literature review.

Medicine
2024

Perioperative blood transfusion management in surgical resection of intracranial meningiomas: A meta-analysis.

Surgical neurology international
2024

[Benefits and Pitfalls of Re-Operation for Recurrent Meningioma].

No shinkei geka. Neurological surgery
2024

Coexisting Meningioma and Glioma in the Same Patient: A Case Report.

Cureus
2024

Bridging the gap: exploring the causal relationship between metformin and tumors.

Frontiers in genetics
2024

NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity.

NPJ precision oncology
2024

Role of scalp nerve block in improving the quality of rehabilitation in patients after meningioma resection: A randomized controlled clinical trial.

Medicine
2024

Exploring the Biological Overlapping Between Brain Calcifications and Tumorgenesis.

Journal of molecular neuroscience : MN
2024

Implications and interchangeability of meningioma biomarkers for clinical trials and clinical practice.

Journal of neuro-oncology
2024

Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy.

Cancer discovery
2024

Primary intracranial peripheral primitive neuroectodermal tumor: lessons from an exceptionally rare neoplasm. Illustrative case.

Journal of neurosurgery. Case lessons
2024

Status epilepticus in patients with brain tumors and metastases: A multicenter cohort study of 208 patients and literature review.

Neurological research and practice
2024

Variations in the genomic profiles and clinical behavior of meningioma by racial and ethnic group.

Journal of neurosurgery
2024

[Indirect causes of maternal deaths (except stroke, cardiovascular diseases and infections) in France 2016-2018].

Gynecologie, obstetrique, fertilite &amp; senologie
2024

Pediatric spinal ependymoma with chromothripsis of chromosome 6: a case report and review of the literature.

Journal of medical case reports
2024

Surgical Management and Outcome of the Planum Sphenoidale Meningioma: A Single-Center Strobe Compliant Study.

World neurosurgery
2024

Risk factors on surgical compliance and its impact on survival outcomes in meningioma patients: a SEER-based retrospective propensity-score matched analysis.

BMC surgery
2024

Extra-Axial Cavernous Angioma: A Case Report and Review of the Literature.

Neurology international
2023

Asymptomatic Presentation of Yellow Oleander Poisoning in a 57-Year-Old Saudi Woman: A Case Report.

Cureus
2024

Epidemiology, Genetics, and DNA Methylation Grouping of Hyperostotic Meningiomas.

Operative neurosurgery (Hagerstown, Md.)
2023

Unusual Presentation of Prostate Cancer: A Case Report.

Cureus
2023

Detection and classification of brain tumor using hybrid deep learning models.

Scientific reports
2024

Optic Nerve Sheath Meningiomas: A National Surveillance, Epidemiology, and End Results (SEER) Database Analysis.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
2023

Meningioma transformation to glioblastoma following stereotactic radiosurgery: A case report and review of the literature.

Surgical neurology international
2023

Supplementary Motor Area Syndrome After Resection of a Dominant Hemisphere Parasagittal Meningioma: A Case Report.

Neurosurgery practice
2023

Operative Strategies for Aplastic Circle of Willis Arteries on CTA in Meningioma Surgery: A Case Report.

Neurosurgery practice
2023

Early Preventive Strategies and CNS Meningioma - Is This Feasible? A Comprehensive Review of the Literature.

World neurosurgery
2023

Disease-Based Prognostication: Neuro-Oncology.

Seminars in neurology
2023

Clinicopathological significance of concurrent ErbB receptor expression in human meningioma.

Molecular and clinical oncology
2023

Collision tumor of squamous cell carcinoma of the scalp and meningioma: A case report.

Radiology case reports
2023

Intracranial meningiomas: an update of the 2021 World Health Organization classifications and review of management with a focus on radiation therapy.

Frontiers in oncology
2023

Frailty and postoperative outcomes in brain tumor patients: a systematic review subdivided by tumor etiology.

Journal of neuro-oncology
2023

A comparison of non-negative matrix underapproximation methods for the decomposition of magnetic resonance spectroscopy data from human brain tumors.

NMR in biomedicine
2023

NOTCH3 drives meningioma tumorigenesis and resistance to radiotherapy.

bioRxiv : the preprint server for biology
2023

The complex role of eicosanoids in the brain: Implications for brain tumor development and therapeutic opportunities.

Biochimica et biophysica acta. Reviews on cancer
2023

Cutaneous lesions and other non-endocrine manifestations of Multiple Endocrine Neoplasia type 1 syndrome.

Frontiers in endocrinology
2023

Associations of race and socioeconomic status with outcomes after intracranial meningioma resection: a systematic review and meta-analysis.

Journal of neuro-oncology
2023

Rare benign lung tumours presenting with high clinical suspicion for malignancy: a case series and review of the literature.

Folia histochemica et cytobiologica
2023

Analysis of recurrence probability following radiotherapy in patients with CNS WHO grade 2 meningioma using integrated molecular-morphologic classification.

Neuro-oncology advances
2023

The clinical and genomic features of seizures in meningiomas.

Neuro-oncology advances
2023

Pediatric meningiomas: A literature review and diagnostic update.

Neuro-oncology advances
2023

The clinical, genetic, and immune landscape of meningioma in patients with NF2-schwannomatosis.

Neuro-oncology advances
2023

Multiple meningiomas: Epidemiology, management, and outcomes.

Neuro-oncology advances
2023

Intragenic β-synuclein rearrangements in malignancy.

Frontiers in oncology
2023

Clinical and genomic differences in supratentorial versus infratentorial NF2 mutant meningiomas.

Journal of neurosurgery
2023

Epigenetic Regulation in Primary CNS Tumors: An Opportunity to Bridge Old and New WHO Classifications.

Cancers
2023

SMARCE1-related meningiomas: A clear example of cancer predisposing syndrome.

European journal of medical genetics
2023

Brain Tumor: A Review of Its Demographic in a Rural Hospital of Sibu in Sarawak, Malaysia.

Asian journal of neurosurgery
2023

Surgical strategies for intracranial meningioma in the molecular era.

Journal of neuro-oncology
2023

Early-onset grade 2-3 diffuse gliomas and schwannomas increase the risk of central nervous system tumors among the patients' relatives.

Neuro-oncology advances
2023

Specific gene expression signatures of low grade meningiomas.

Frontiers in oncology
2023

Coexistent meningioma in a patient with primary familial brain calcification: A case report.

Radiology case reports
2023

Imaging of pituitary tumors: an update with the 5th WHO Classifications-part 2. Neoplasms other than PitNET and tumor-mimicking lesions.

Japanese journal of radiology
2023

Epstein-Barr virus-associated primary intracranial leiomyosarcoma in an immunocompetent patient: illustrative case.

Journal of neurosurgery. Case lessons
2022

Gastrointestinal Stromal Tumor With a Rare Associated Meningioma: A Case Report.

Cureus
2023

Two unique BAP1 pathogenic variants identified in the same family by panel cascade testing.

Familial cancer
2023

Clinical implementation of integrated molecular-morphologic risk prediction for meningioma.

Brain pathology (Zurich, Switzerland)
2022

Differentiation between various types and subtypes of intracranial meningiomas with advanced MRI.

SA journal of radiology
2023

Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022

Schizophrenia-Like Psychosis Presented in a Patient With a Temporal Lobe Tumor: A Case Report.

Cureus
2023

Six case reports of NTHL1-associated tumor syndrome further support it as a multi-tumor predisposition syndrome.

Clinical genetics
2023

pSlugS158 Immunohistochemistry is Useful in Grading Meningioma.

International journal of surgical pathology
2022

Quality of life after resection of a meningioma-A cross-cultural comparison of Indian and Australian patients.

PloS one
2022

BAP1 Tumour Predisposition Syndrome Due to Whole BAP1 Gene Deletion.

Case reports in genetics
2022

Oculomotor nerve palsy in neurofibromatosis type 2.

Radiology case reports
2023

Coexisting lipomatous meningioma and glioblastoma in Cowden syndrome: A unique tumor association.

Neuropathology : official journal of the Japanese Society of Neuropathology
2022

Supratentorial extra-axial RELA fusion-positive ependymoma misdiagnosed as meningioma by intraoperative histological and cytological examinations: a case report.

Journal of medical case reports
2022

Extra-Axial supratentorial anaplastic ependymoma: Unusual location of an aggressive tumor, A case report.

Indian journal of pathology &amp; microbiology
2022

Caspase 8 Expression Patterns in Meningiomas: A Tissue Microarray Digital Image Analysis.

Cureus
2022

TRAF7 somatic mosaicism in a patient with bilateral optic nerve sheath meningiomas: illustrative case.

Journal of neurosurgery. Case lessons
2022

Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours.

Nature reviews. Neurology
2022

[Molecular Biological Background of Neurofibromatosis Type 2].

No shinkei geka. Neurological surgery
2022

Genomic profiling of sporadic multiple meningiomas.

BMC medical genomics
2022

Interesting presentation of postnatal depression and infant failure to thrive.

BMJ case reports
2022

Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins.

Cancers
2022

Examination of Genetic Susceptibility in Radiation-Associated Meningioma.

Radiation research
2022

Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas.

Nature communications
2022

Intracranial Osteoma: Unusual Etiology of Chronic Daily Headaches.

Cureus
2021

Utilization of Cerebrospinal Fluid Proteome Analysis in the Diagnosis of Meningioma: A Systematic Review.

Cureus
2021

Defining the Spectrum, Treatment and Outcome of Patients With Genetically Confirmed Gorlin Syndrome From the HIT-MED Cohort.

Frontiers in oncology
2021

Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo.

Cancers
2022

The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications.

Journal of neuro-oncology
2021

Receptor Tyrosine Kinases as Candidate Prognostic Biomarkers and Therapeutic Targets in Meningioma.

International journal of molecular sciences
2021

Relapse of Psychosis Status Post Meningioma Resection.

Health psychology research
2021

Negative Impact of COVID-19 Upon Primary Brain Tumor Care.

Cureus
2021

Genomic Biomarkers of Meningioma: A Focused Review.

International journal of molecular sciences
2022

Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
2021

Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2021

Description of Two Families with New Mutations in Familial Cerebral Cavernous Malformations Genes.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
2021

Coexistent vestibular schwannoma and meningioma in a patient without neurofibromatosis: A case report and review of literature.

World journal of clinical cases
2021

Germline BAP1 Mutation in a Family With Multi-Generational Meningioma With Rhabdoid Features: A Case Series and Literature Review.

Frontiers in oncology
2021

Management experience of pediatric meningioma in a Mexican reference center.

Annals of diagnostic pathology
2021

Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations.

The New England journal of medicine
2022

Bilateral Diffuse Uveal Melanocytic Proliferation in a Patient with Recurrent Frontal Lobe Meningioma.

Ocular immunology and inflammation
2021

Intracranial meningioma in two coeval adult cats from the same litter.

JFMS open reports
2021

It's All Due to the Thyroid: Lessons Learnt From a Patient's Perspective.

Cureus
2021

Meningioma genomics: a therapeutic challenge for clinicians.

Journal of integrative neuroscience
2021

Biological Treatments of Neurofibromatosis Type 2 and Other Skull Base Disorders.

Otolaryngologic clinics of North America
2021

Patient-specific virtual reality technology for complex neurosurgical cases: illustrative cases.

Journal of neurosurgery. Case lessons
2021

Epidemiological distribution of primary central nervous system tumors in the Western Province of Saudi Arabia: a local registry from neuroscience-affiliated centers.

Epidemiology and health
2021

Venous Anatomy Influence on the Approach Selection of a Petroclival Clear Cell Meningioma With Associated Multiple Spinal Meningiomas: 2-Dimensional Operative Video.

Operative neurosurgery (Hagerstown, Md.)
2021

Multiple meningiomas arising within the same hemisphere associated with Li-Fraumeni syndrome.

Surgical neurology international
2023

A Novel Pathogenic Variant in the MN1 Gene in a Patient Presenting with Rhombencephalosynapsis and Craniofacial Anomalies, Expanding MN1 C-terminal Truncation Syndrome.

Journal of pediatric genetics
2021

Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

The Lancet. Oncology
2021

Innumerable Meningiomas Arising in a Patient With Tuberous Sclerosis Complex Decades After Radiation Therapy.

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
2021

SWI/SNF deficient central nervous system neoplasms.

Seminars in diagnostic pathology
2021

Case report 68Ga-DOTATATE of optic nerve sheath meningioma.

American journal of ophthalmology case reports
2021

KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo.

Cancer letters
2022

Case Series of Skull Base Meningioma Resection in the Octogenarian Population.

Journal of neurological surgery. Part B, Skull base
2021

Meningioma: A Pathology Perspective.

Neurosurgery
2021

A Preliminary Report on Quality of Life and Sexual Function in Brain Tumor Patients.

The journal of sexual medicine
2021

Epidemiology and survival of patients with spinal meningiomas: A SEER analysis.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2021

Interdisciplinary Approaches to Survivorship with a Focus on the Low-grade and Benign Brain Tumor Populations.

Current oncology reports
2021

Intracranial angiomatoid fibrous histiocytoma with rhabdoid features: a mimic of rhabdoid meningioma.

Brain tumor pathology
2021

A Case of Multiple Adenomatous Colon Polyps and Meningiomas.

Gastroenterology
2020

Effect of lifestyle and dietary factors in the development of brain tumors.

Journal of family medicine and primary care
2020

Co-expression of CD34 and h-caldesmon in a benign meningioma-like dermal neoplasm, a case report.

Dermatology reports
2020

Acute Necrotizing Encephalitis as a Probable Association of COVID-19.

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine
2020

Familial Nervous System Tumor Syndromes.

Continuum (Minneapolis, Minn.)
2021

mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.

The Journal of biological chemistry
2020

Demographic study of brain tumour in a neurosurgical department in Terengganu, Malaysia.

The Medical journal of Malaysia
2021

The importance of genetic counseling and screening for people with pathogenic SMARCE1 variants: A family study.

American journal of medical genetics. Part A
2021

Predictive Model and Online Calculator for Discharge Disposition in Brain Tumor Patients.

World neurosurgery
2020

Incidence, Mortality, and Survival Trends of Primary CNS Tumors in Cali, Colombia, From 1962 to 2019.

JCO global oncology
2020

Nasopharyngeal B-cell lymphoma with pan-hypopituitarism and oculomotor nerve palsy: a case report and review of the literature.

BMC endocrine disorders
2020

Forkhead Box M1 promotes the growth and tube formation of human malignant meningioma cells via the aryl hydrocarbon receptor signaling pathway.

Folia neuropathologica
2020

Familial Pediatric Clear Cell Meningioma With Germline SMARCE1 Mutation in the United States.

Journal of neuropathology and experimental neurology
2020

ARMC5 Primary Bilateral Macronodular Adrenal Hyperplasia Associated with a Meningioma: A Family Report.

Case reports in endocrinology
2020

Subsequent Neoplasm Risk Associated With Rare Variants in DNA Damage Response and Clinical Radiation Sensitivity Syndrome Genes in the Childhood Cancer Survivor Study.

JCO precision oncology
2019

Molecular mechanisms of ARMC5 mutations in adrenal pathophysiology.

Current opinion in endocrine and metabolic research
2021

Familial Tuberculum Sellae Meningiomas.

The Journal of craniofacial surgery
2020

Occupational and ambient radiation exposures from Lu-177 DOTATATE during targeted therapy.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
2020

GATA-4, a potential novel therapeutic target for high-grade meningioma, regulates miR-497, a potential novel circulating biomarker for high-grade meningioma.

EBioMedicine
2020

Benign and malignant tumors of the central nervous system and pregnancy.

Handbook of clinical neurology
2020

The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma.

Cancers
2020

Determining the unmet needs of patients with intracranial meningioma-a qualitative assessment.

Neuro-oncology practice
2020

End of life care for patients with meningioma.

Handbook of clinical neurology
2020

Multiple primary tumors: a case report and review of the literature.

BMC musculoskeletal disorders
2020

Inherited genetic syndromes and meningiomas.

Handbook of clinical neurology
2020

A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas.

Frontiers in neurology
2020

Intracranial emergencies during pregnancy requiring urgent neurosurgical treatment.

Clinical neurology and neurosurgery
2020

PiTMaP: A New Analytical Platform for High-Throughput Direct Metabolome Analysis by Probe Electrospray Ionization/Tandem Mass Spectrometry Using an R Software-Based Data Pipeline.

Analytical chemistry
2020

The utility of 3-dimensional-printed models for skull base meningioma surgery.

Annals of translational medicine
2020

Demographics and outcomes of meningioma patients treated at a tertiary care center in the Middle East.

Clinical neurology and neurosurgery

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Meningioma familiar múltiplo.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Meningioma familiar múltiplo

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ainda não achamos doenças com sintomas parecidos o suficiente.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. STING activation induces cytotoxic and immune responses in meningiomas via inflammatory cell death pathways.
    Nature communications· 2026· PMID 41680157mais citado
  2. Association Between miRNAs and the Diagnosis, Prognosis, and Recurrence of Patients with Meningioma: A Systematic Review.
    Cellular and molecular neurobiology· 2026· PMID 41654683mais citado
  3. KMT2C Loss Promotes NF2-Wildtype Meningioma Progression and Ferroptosis Sensitivity via Epigenetic Repression of Hippo Signaling.
    Advanced science (Weinheim, Baden-Wurttemberg, Germany)· 2026· PMID 41642951mais citado
  4. Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis.
    Annals of internal medicine· 2026· PMID 41359966mais citado
  5. French translation and preliminary psychometric evaluation of the Meningioma Quality of Life questionnaire (MQOL-FR).
    Neuro-Chirurgie· 2026· PMID 41866074mais citado
  6. Familial multiple fetal cerebral arteriovenous malformations: a case report of maternal genetic susceptibility and fetal manifestation.
    Front Genet· 2025· PMID 41555917recente
  7. Familial multiple discoid fibromas: clinical features and a brief overview of the literature.
    An Bras Dermatol· 2026· PMID 41506187recente
  8. Exome Sequencing and Molecular Modeling Reveal Novel Loci in Familial Multiple Sclerosis: The Importance of BTNL3 and BTNL8 in Disease Pathogenesis.
    Mol Neurobiol· 2025· PMID 41324801recente
  9. Exome Sequencing Uncovers Genetic Drivers of Multiple Sclerosis in a Multiplex Family.
    Genes (Basel)· 2025· PMID 41300763recente
  10. Familial multiple sclerosis is associated with accelerated progression to secondary progressive phase: a retrospective single-center cohort study.
    J Neurol· 2025· PMID 41201681recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:263662(Orphanet)
  2. MONDO:0016995(MONDO)
  3. GARD:17260(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q56013917(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Meningioma familiar múltiplo
Compêndio · Raras BR

Meningioma familiar múltiplo

ORPHA:263662 · MONDO:0016995
Prevalência
Unknown
Herança
Autosomal dominant
CID-10
D32.9 · Neoplasia benigna das meninges, não especificada
CID-11
Início
All ages
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C4707361
EuropePMC
Wikidata
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades